Literature DB >> 517883

Complete remissions in metastatic breast cancer treated with combination drug therapy.

S S Legha, A U Buzdar, T L Smith, G N Hortobagyi, K D Swenerton, G R Blumenschein, E A Gehan, G P Bodey, E J Freireich.   

Abstract

One hundred sixteen patients with metastatic breast cancer who achieved complete remission with combination chemotherapy were analyzed to ascertain the factors that affect the duration of complete remission and the patterns of relapse. The median duration of complete remission was 17 months. Disease recurred in 81 patients (70%) at periods ranging from 3 to 44 months after achievement of complete remission. The duration of complete remission was inversely related to the bulk of metastatic tumor. Twenty-three patients treated with combined oophorectomy and chemotherapy experienced the longest remissions (median duration of 33 months); only eight (35%) of them have relapsed. Seventy-six percent of the relapses occurred in previously known sites of tumor involvement; most of the remainder involved the brain. The short duration of complete remissions and tendency to relapse in sites of initial involvement suggest that patients with metastatic breast cancer who achieved complete remission with combination chemotherapy still had substantial residual tumor. Consolidation treatments, using hormonal therapy and non-cross-resistant chemotherapy along with irradiation to initial sites of metastases, whould be investigated to ascertain their usefulness in prolonging the remissions.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 517883     DOI: 10.7326/0003-4819-91-6-847

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

Review 1.  Dose-intensified treatment of breast cancer: current results.

Authors:  C von Schilling; F Herrmann
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

2.  Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer.

Authors:  E G de Vries; S Rodenhuis; H C Schouten; P S Hupperets; W V Dolsma; J V Lebesque; G H Blijham; M Bontenbal; N H Mulder
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF).

Authors:  J A Neidhart
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

Review 4.  An assessment of current achievements in the systemic management of breast cancer.

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

Review 5.  Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three?

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

6.  Adjuvant chemotherapy for early breast cancer.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

7.  Breast cancer and thoracic metastases: review of 119 patients.

Authors:  H Kreisman; N Wolkove; H S Finkelstein; C Cohen; R Margolese; H Frank
Journal:  Thorax       Date:  1983-03       Impact factor: 9.139

8.  Breast cancer surveillance--a cost-effective strategy.

Authors:  D V Schapira
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.

Authors:  R V Iaffaioli; A Tortoriello; G Facchini; M Santangelo; L Bucci; L Fei; N Di Martino; G Mantovani; F Caponigro
Journal:  Breast Cancer Res Treat       Date:  1995-09       Impact factor: 4.872

10.  Cure of advanced L1210 leukemia after correction of abnormal red blood cell deformability.

Authors:  M H Cohen
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.